Further studies have found that a combined dose of PIK-75 and vemurafenib, a BRAF inhibitor, halts both the PI3K/AKT and mitogen-activated protein kinase pathways, which proved to be effective against early passage cell lines derived from patient tumor samples and on melanoma cell lines resistant to either vemurafenib or dabrafenib [225]. Here, BRAF is linked to neoplasm.